Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124460 | 0.86 | GRM2 (0.48) | SLC6A4KCNH2LMNAGBA1CYP1A2 | |
| SCHEMBL1039759 | 0.82 | BCHE (0.50) | SLC6A4LMNABACE1HTTGLA | |
| SCHEMBL2635104 | 0.81 | POLB (0.50) | SLC6A4KCNH2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL662406 | 0.79 | LMNA (0.50) | SLC6A4KCNH2LMNAGBA1CYP1A2 | |
| SCHEMBL12757504 | 0.77 | POLB (0.42) | SLC6A4KCNH2LMNAGBA1CYP1A2 | |
| SCHEMBL12757502 | 0.77 | CSNK2A1 (0.44) | SLC6A4KCNH2LMNAGBA1CYP1A2 | |
| SCHEMBL23124871 | 0.76 | KDM1A (0.57) | SLC6A4KCNH2LMNAGBA1CYP1A2 | |
| SCHEMBL5736421 | 0.76 | CYP1A2 (0.43) | SLC6A4KCNH2LMNAGBA1CYP1A2 | |
| SCHEMBL2635861 | 0.76 | SIGMAR1 (0.44) | SLC6A4TSHRTDP1BACE1HTT | |
| SCHEMBL5271971 | 0.76 | KDM4E (0.51) | SLC6A4KCNH2LMNATDP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| CN-101395135-A | Novel primary amides | ACTELION PHARMACEUTICALS LTD (CH) | 2009-03-25 | — | — | CN | disclosed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007049224-A1 | NOVEL HEXAHYDRO- OR OCTAHYDRO-CYCLOPENTA[C]PYRROLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | SLC6A4 1352/4885KCNH2 1215/4885LMNA 1559/4885 |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | SLC6A4 413/4885KCNH2 729/4885LMNA 915/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | SLC6A4 2577/4885KCNH2 1536/4885LMNA 1587/4885 |
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | SLC6A4 181/4885KCNH2 656/4885LMNA 1225/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | SLC6A4 504/4885KCNH2 476/4885LMNA 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.